Mitochondrial dysfunction: a new target for traditional Chinese medicine in the treatment of chronic heart failure

Abstract

Chronic heart failure (CHF) remains a global health challenge with limited therapeutic options. Mitochondrial dysfunction is a key pathological feature, and traditional Chinese medicine (TCM) shows unique potential in targeting this mechanism. Evidence from human and animal models of heart failure indicates that TCM can restore mitochondrial function by regulating mitochondrial Ca²⁺ homeostasis, oxidative stress, energy metabolism, mitochondrial dynamics, and mitophagy. TCM-based treatment of CHF offers notable clinical advantages, including improved therapeutic efficacy, enhanced cardiac function, and reduced incidence of major cardiovascular events. Experimental studies demonstrate that TCM decoctions and monomers modulate signaling pathways such as PPAR-RXRα, NF-κB, and PI3K/AKT to alleviate oxidative stress. TCM also increases AMPK activity via phosphorylation of PGC-1α, indirectly promoting mitochondrial biogenesis; attenuates calcium influx and enhances Ca²⁺ reuptake, thereby ameliorating myocardial mitochondrial dysfunction in CHF; and improves CHF by rebalancing mitochondrial dynamics and autophagy.

Keywords

Mitochondrial dysfunction / Traditional Chinese medicine / Chronic heart failure

Funding

This work was supported by the National Natural Science Foundation of China (No. 82374195).

Supporting information

Supplementary data associated with this article can bere-quested by sending E-mail to the corresponding authors.

Declaration of competing interest

These authors declare no conflict of interest.

References

[1] Khan MS, Shahid I, Bennis A, et al. Global epidemiology of heart failure. Nat Rev Cardiol. 2024; 21(10):717-734. https://doi.org/10.1038/s41569-024-01046-6.

[2] Cai WW, Qin YY, Ge F, et al. Xin-Ji-Er-Kang balances mitochondrial fusion and fission to protect cardiomyocytes in mice with heart failure by regulating the ERα/SIRT3 pathway. Phytomedicine. 2025; 139:156420. https://doi.org/10.1016/j.phymed.2025.156420.

[3] Zhang XH, Chang X, Chai RN, et al. Xin-Fu-Kang oral liquid mitigates chronic heart failure through NR4A1-Dependent regulation of endoplasmic reticulum-mitochondrial crosstalk in Cardiomyocytes. Phytomedicine. 2025; 140:156467. https://doi.org/10.1016/j.phymed.2025.156467.

[4] Lin LW, Xu HL, Yao ZY, et al. Jin-Xin-Kang alleviates heart failure by mitigating mitochondrial dysfunction through the Calcineurin/Dynamin-Related Protein 1 signaling pathway. J Ethnopharmacol. 2024; 335:118685. https://doi.org/10.1016/j.jep.2024.118685.

[5] Li XL, Zhang J, Huang J, et al. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. J Am Coll Cardiol. 2013; 62(12):1065-1072. https://doi.org/10.1016/j.jacc.2013.05.035.

[6] Cheang IF, Yao WM, Zhou YL, et al. The traditional Chinese medicine Qiliqiangxin in heart failure with reduced ejection fraction: a randomized, double-blind, placebo-controlled trial. Nat Med. 2024; 30(8):2295-2302. https://doi.org/10.1038/s41591-024-03169-2.

[7] Wang Y, Wang J, Lv W, et al. Clinical intervention effect of Xuefu Zhuyu decoction on chronic heart failure complicated with depression. World J Psychiatry. 2024; 14(6):857-865. https://doi.org/10.5498/wjp.v14.i6.857.

[8] Wei HM, Wu HJ, Yu W, et al. Shenfu decoction as adjuvant therapy for improving quality of life and hepatic dysfunction in patients with symptomatic chronic heart failure. J Ethnopharmacol. 2015; 169:347-355. https://doi.org/10.1016/j.jep.2015.04.016.

[9] Li Q, Su LS, Zhou RJ, et al. Efficacy and safety of Yangyin Shuxin Decoction-a Chinese herbal medicine formula for heart failure with preserved ejection fraction: a randomized controlled trial. Evid-Based Compl Alt. 2022; 2022:1486366. https://doi.org/10.1155/2022/1486366.

[10] Chen YH, Fan LH, Zhang T, et al. Effectiveness of Zhuling Decoction on diuretic resistance in patients with heart failure: a randomized, controlled trial. J Tradit Chin Med. 2022; 42(3):439-445. https://doi.org/10.19852/j.cnki.jtcm.20220311.003.

[11] Du KJ, Liu JJ, Tan NN, et al. The effects of qishen granules for patients with chronic heart failure: a multicenter randomized double-blind placebo-controlled trial. Front Pharmacol. 2022; 13:1017734. https://doi.org/10.3389/fphar.2022.1017734.

[12] Liu SP, Zhou JG, Jin Y, et al. Therapeutic efficacy of Shexiang Baoxin Pill combined with exercise in patients with heart failure with preserved ejection fraction: a single-center, double-blind, randomized controlled trial. Chin J Integr Med. 2023; 29(2):99-107. https://doi.org/10.1007/s11655-022-3627-3.

[13] Li Y, Zhang L, Lv SZ, et al. Efficacy and safety of oral Guanxinshutong capsules in patients with stable angina pectoris in China: a prospective, multicenter, double-blind, placebo-controlled, randomized clinical trial. BMC Compl Alt Med. 2019; 19(1):363. https://doi.org/10.1186/s12906-019-2778-z.

[14] Mao JY, Zhang J, Lam CSP, et al. Qishen Yiqi dripping pills for chronic ischaemic heart failure: results of the CACT-IHF randomized clinical trial. ESC Heart Fail. 2020; 7(6):3881-3890. https://doi.org/10.1002/ehf2.12980.

[15] Xian SX, Yang ZQ, Lee J, et al. A randomized, double-blind, multicenter, placebo-controlled clinical study on the efficacy and safety of Shenmai injection in patients with chronic heart failure. J Ethnopharmacol. 2016; 186:136-142. https://doi.org/10.1016/j.jep.2016.03.066.

[16] Wang SM, Ye LF, Wang LH. Shenmai Injection improves energy metabolism in patients with heart failure: a randomized controlled trial. Front Pharmacol. 2020; 11:459. https://doi.org/10.3389/fphar.2020.00459.

[17] Xue JG, Xu Y, Deng Y, et al. The efficacy and safety of Xinmailong Injection in patients with chronic heart failure: a multicenter randomized double-blind placebo-controlled trial. J Altern Complem Med. 2019; 25(8):856-860. https://doi.org/10.1089/acm.2019.0030.

[18] Yeh GY, McCarthy EP, Wayne PM, et al. Tai chi exercise in patients with chronic heart failure: a randomized clinical trial. Arch Intern Med. 2011; 171(8):750-757. https://doi.org/10.1001/archinternmed.2011.150.

[19] Barrow DE, Bedford A, Ives G, et al. An evaluation of the effects of Tai Chi Chuan and Chi Kung training in patients with symptomatic heart failure: a randomised controlled pilot study. Postgrad Med J. 2007; 83(985):717-721. https://doi.org/10.1136/pgmj.2007.061267.

[20] Chen DM, Yu WC, Hung HF, et al. The effects of Baduanjin exercise on fatigue and quality of life in patients with heart failure: A randomized controlled trial. Eur J Cardiovasc Nurs. 2018; 17(5):456-466. https://doi.org/10.1177/1474515117744770.

[21] Li JG, Yu ML, Wang YH, et al. Baduanjin for ischemic heart failure with mildly reduced/preserved ejection fraction (BEAR Trial): a randomized controlled trial. J Evid Based Med. 2024; 17(3):526-534. https://doi.org/10.1111/jebm.12631.

[22] Sturgis J, Singh R, Caron QR, et al. Modeling aging and retinal degeneration with mitochondrial DNA mutation burden. Aging Cell. 2024; 23(11):e14282. https://doi.org/10.1111/acel.14282.

[23] Grevendonk L, Connell NJ, McCrum C, et al. Impact of aging and exercise on skeletal muscle mitochondrial capacity, energy metabolism, and physical function. Nat Commun. 2021; 12(1):4773. https://doi.org/10.1038/s41467-021-24956-2.

[24] Chen WH, Shen ZL, Dong WX, et al. Polygonatum sibiricum polysaccharide ameliorates skeletal muscle aging via mitochondria-associated membrane-mediated calcium homeostasis regulation. Phytomedicine. 2024; 129:155567. https://doi.org/10.1016/j.phymed.2024.155567.

[25] Ni XC, Wang HF, Cai YY, et al. Ginsenoside Rb1 inhibits astrocyte activation and promotes transfer of astrocytic mitochondria to neurons against ischemic stroke. Redox Biol. 2022; 54:102363. https://doi.org/10.1016/j.redox.2022.102363.

[26] Zhao Y, Li Q, Zhao WJ, et al. Astragaloside IV and cycloastragenol are equally effective in inhibition of endoplasmic reticulum stress-associated TXNIP/NLRP3 inflammasome activation in the endothelium. J Ethnopharmacol. 2015; 169:210-218. https://doi.org/10.1016/j.jep.2015.04.030.

[27] Yen JH, Huang HS, Chuang CJ, et al. Activation of dynamin-related protein 1-dependent mitochondria fragmentation and suppression of osteosarcoma by cryptotanshinone. J Exp Clin Cancer Res. 2019; 38(1):42. https://doi.org/10.1186/s13046-018-1008-8.

[28] Xia K, Jin ZY, Qiu QM, et al. Ligustilide alleviates oxidative stress during renal ischemia-reperfusion injury through maintaining Sirt3-dependent mitochondrial homeostasis. Phytomedicine. 2024; 134:155975. https://doi.org/10.1016/j.phymed.2024.155975.

[29] Sekhar RV. GlyNAC supplementation improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, aging hallmarks, metabolic defects, muscle strength, cognitive decline, and body composition: implications for healthy aging. J Nutr. 2021; 151(12):3606-3616. https://doi.org/10.1093/jn/nxab309.

[30] Grel H, Woznica D, Ratajczak K, et al. Mitochondrial dynamics in neurodegenerative diseases: unraveling the role of fusion and fission processes. Int J Mol Sci. 2023; 24(17):17033. https://doi.org/10.3390/ijms241713033.

[31] Hinton A Jr. Claypool SM, Neikirk K, et al. Mitochondrial structure and function in human heart failure. Circ Res. 2024; 135(2):372-396. https://doi.org/10.1161/circresaha.124.323800.

[32] Mongirdienė A, Skrodenis L, Varoneckaitė L, et al. Reactive oxygen species induced pathways in heart failure pathogenesis and potential therapeutic strategies. Biomedicines. 2022; 10(3):602. http://dx.doi.org/10.3390/biomedicines10030602.

[33] Hu YC, Chen XY, Zhao QM, et al. Berberine improves cardiac insufficiency through AMPK/PGC-1α signaling-mediated mitochondrial homeostasis and apoptosis in HFpEF mice. Int Immunopharmacol. 2025; 155:114613. https://doi.org/10.1016/j.intimp.2025.114613.

[34] Pan GP, Cui BY, Han MM, et al. Puerarin inhibits NHE 1 activity by interfering with the p38 pathway and attenuates mitochondrial damage induced by myocardial calcium overload in heart failure rats. Acta Biochim Biophys Sin (Shanghai). 2024; 56(2):270-279. https://doi.org/10.3724/abbs.2023269.

[35] Wang Z, Xu Y, Wang ML, et al. TRPA1 inhibition ameliorates pressure overload-induced cardiac hypertrophy and fibrosis in mice. EBioMedicine. 2018; 36:54-62. https://doi.org/10.1016/j.ebiom.2018.08.022.

[36] Pekson R, Liang FG, Axelrod JL, et al. The mitochondrial ATP synthase is a negative regulator of the mitochondrial permeability transition pore. Proc Natl Acad Sci USA. 2023; 120(51):e2303713120. https://doi.org/10.1073/pnas.2303713120.

[37] de Wit-Verheggen VHW, Schrauwen-Hinderling VB, Brouwers K, et al. PCr/ATP ratios and mitochondrial function in the heart: a comparative study in humans. Sci Rep. 2023; 13(1):8346. https://doi.org/10.1038/s41598-023-35041-7.

[38] Savvatis K, Vissing CR, Klouvi L, et al. Cardiac outcomes in adults with mitochondrial diseases. J Am Coll Cardiol. 2022; 80(15):1421-1430. https://doi.org/10.1016/j.jacc.2022.08.716.

[39] Chen X, Gan BY. SLC25A39 links mitochondrial GSH sensing with iron metabolism. Mol Cell. 2024; 84(4):616-618. https://doi.org/10.1016/j.molcel.2023.12.037.

[40] Tang Y, Wu JR, Sun XJ, et al. Cardiolipin oxidized by ROS from complex II acts as a target of gasdermin D to drive mitochondrial pore and heart dysfunction in endotoxemia. Cell Rep. 2024; 43(5):114237. https://doi.org/10.1016/j.celrep.2024.114237.

[41] Wang XJ, Zhang L, Feng MW, et al. ELA-11 protects the heart against oxidative stress injury induced apoptosis through ERK/MAPK and PI3K/AKT signaling pathways. Front Pharmacol. 2022; 13:873614. https://doi.org/10.3389/fphar.2022.873614.

[42] Pouleur AC, Menghoum N, Cumps J, et al. Plasma myo-inositol elevation in heart failure: clinical implications and prognostic significance. Results from the BElgian and CAnadian MEtabolomics in HFpEF (BECAME-HF) research project. EBioMedicine. 2024; 107:105264. https://doi.org/10.1016/j.ebiom.2024.105264.

[43] Lopaschuk GD, Karwi QG, Tian R, et al. Cardiac energy metabolism in heart failure. Circ Res. 2021; 128(10):1487-1513. https://doi.org/10.1161/circresaha.121.318241.

[44] Sunagawa Y, Kawaguchi S, Miyazaki Y, et al. Auraptene, a citrus peel-derived natural product, prevents myocardial infarction-induced heart failure by activating PPARα in rats. Phytomedicine. 2022; 107:154457. https://doi.org/10.1016/j.phymed.2022.154457.

[45] Castañé H, Jiménez-Franco A, Hernández-Aguilera A, et al. Multi-omics profiling reveals altered mitochondrial metabolism in adipose tissue from patients with metabolic dysfunction-associated steatohepatitis. EBioMedicine. 2025; 111:105532. https://doi.org/10.1016/j.ebiom.2024.105532.

[46] Liu CX, Guo XY, Zhou YB, et al. AMPK signalling pathway: a potential strategy for the treatment of heart failure with Chinese medicine. J Inflamm Res. 2023; 16:5451-5464. https://doi.org/10.2147/jir.S441597.

[47] Li XF, Liang JY, Qin AQ, et al. Protective effect of Di'ao Xinxuekang Capsule against doxorubicin-induced chronic cardiotoxicity. J Ethnopharmacol. 2022; 287:114943. https://doi.org/10.1016/j.jep.2021.114943.

[48] Li S, Liu H, Li Y, et al. Shen-Yuan-Dan Capsule attenuates verapamil-induced zebrafish heart failure and exerts antiapoptotic and anti-inflammatory effects via reactive oxygen species-induced NF-κB pathway. Front Pharmacol. 2021; 12:626515. https://doi.org/10.3389/fphar.2021.626515.

[49] Tang TJ, Wang X, Wang L, et al. Liquiritin inhibits H₂O₂-induced oxidative stress injury in H9c2 cells via the AMPK/SIRT1/NF-κB signaling pathway. J Food Biochem. 2022; 46(10):e14351. https://doi.org/10.1111/jfbc.14351.

[50] Li XM, Zeng LF, Qu ZX, et al. Huoxin pill protects verapamil-induced zebrafish heart failure through inhibition of oxidative stress-triggered inflammation and apoptosis. Heliyon. 2024; 10(1):e23402. https://doi.org/10.1016/j.heliyon.2023.e23402.

[51] Xu S, Wang YY, Yu MY, et al. LongShengZhi Capsule inhibits doxorubicin-induced heart failure by anti-oxidative stress. Biomed Pharmacother. 2020; 123:109803. https://doi.org/10.1016/j.biopha.2019.109803.

[52] Wu ZW, Zhao XK, Miyamoto A, et al. Effects of steroidal saponins extract from Ophiopogon japonicus root ameliorates doxorubicin-induced chronic heart failure by inhibiting oxidative stress and inflammatory response. Pharm Biol. 2019; 57(1):176-183. https://doi.org/10.1080/13880209.2019.1577467.

[53] Shao MY, Guo DQ, Lu WJ, et al. Identification of the active compounds and drug targets of Chinese medicine in heart failure based on the PPARs-RXRα pathway. J Ethnopharmacol. 2020; 257:112859. https://doi.org/10.1016/j.jep.2020.112859.

[54] Feng JL, Guo JY, Yan JR, et al. Luhong Formula and hydroxysafflor yellow A protect cardiomyocytes by inhibiting autophagy. Phytomedicine. 2023; 110:154636. https://doi.org/10.1016/j.phymed.2022.154636.

[55] Zhang X, Shao Z, Ni YC, et al. Salsolinol improves angiotensin II-induced myocardial fibrosis in vitro via inhibition of LSD 1 through regulation of the STAT3/Notch-1 signaling pathway. Exp Ther Med. 2023; 26(5):527. https://doi.org/10.3892/etm.2023.12226.

[56] Xu X, Li SN, Wang T, et al. Mitigation of myocardial ischemia/reperfusion-induced chronic heart failure via Shexiang Baoxin Pill-mediated regulation of the S1PR1 signaling pathway. Phytomedicine. 2024; 128:155390. https://doi.org/10.1016/j.phymed.2024.155390.

[57] Chen LQ, Zhou XH, Deng YJ, et al. Zhenwu decoction ameliorates cardiac hypertrophy through activating sGC (soluble guanylate cyclase)-cGMP (cyclic guanosine monophosphate)-PKG (protein kinase G) pathway. J Ethnopharmacol. 2023; 300:115705. https://doi.org/10.1016/j.jep.2022.115705.

[58] Li ZR, Zhou DY, Wu TC, et al. A novel glycopeptide from mountain-cultivated ginseng residue protects type 2 diabetic symptoms-induced heart failure. J Ethnopharmacol. 2025; 336:118723. https://doi.org/10.1016/j.jep.2024.118723.

[59] Gao ZW, Zhang X, Zhuo QY, et al. Metabolomics and integrated network pharmacology analysis reveal attenuates cardiac hypertrophic mechanisms of HuoXin pill. J Ethnopharmacol. 2022; 292:115150. https://doi.org/10.1016/j.jep.2022.115150.

[60] Wang B, Yang Q, Bai WW, et al. Tongxinluo protects against pressure overload-induced heart failure in mice involving VEGF/Akt/eNOS pathway activation. PLoS One. 2014; 9(6):e98047. https://doi.org/10.1371/journal.pone.0098047.

[61] Zhang Y, Li C, Meng H, et al. BYD ameliorates oxidative stress-induced myocardial spoptosis in heart failure post-acute myocardial infarction via the P38 MAPK-CRYAB signaling pathway. Front Physiol. 2018; 9:505. https://doi.org/10.3389/fphys.2018.00505.

[62] Pang LZ, Ju AC, Zheng XJ, et al. YiQiFuMai Powder Injection attenuates coronary artery ligation-induced myocardial remodeling and heart failure through modulating MAPKs signaling pathway. J Ethnopharmacol. 2017; 202:67-77. https://doi.org/10.1016/j.jep.2017.02.032.

[63] Yang J, Sun WJ, Sun JF, et al. Guanxintai exerts protective effects on ischemic cardiomyocytes by mitigating oxidative stress. Evid-Based Compl Alt. 2017; 2017:4534387. https://doi.org/10.1155/2017/4534387.

[64] Shi X, Cao Y, Wang HY, et al. Vaccarin ameliorates doxorubicin-induced cardiotoxicity via inhibition of p 38 MAPK mediated mitochondrial dysfunction. J Cardiovasc Transl Res. 2024; 17(5):1155-1171. https://doi.org/10.1007/s12265-024-10525-7.

[65] Yuan CY, Wu Z, Jin CL, et al. Qiangxin recipe improves doxorubicin-induced chronic heart failure by enhancing KLF5-mediated glucose metabolism. Phytomedicine. 2023; 112:154697. https://doi.org/10.1016/j.phymed.2023.154697.

[66] Pan LJ, Xu ZC, Wen M, et al. Xinbao Pill ameliorates heart failure via regulating the SGLT1/AMPK/PPARα axis to improve myocardial fatty acid energy metabolism. Chin Med. 2024; 19(1):82. https://doi.org/10.1186/s13020-024-00959-1.

[67] Yu SY, Qian H, Tian DW, et al. Linggui Zhugan Decoction activates the SIRT1-AMPK-PGC1α signaling pathway to improve mitochondrial and oxidative damage in rats with chronic heart failure caused by myocardial infarction. Front Pharmacol. 2023; 14:1074837. https://doi.org/10.3389/fphar.2023.1074837.

[68] Wu RM, Jiang B, Li H, et al. A network pharmacology approach to discover action mechanisms of Yangxinshi Tablet for improving energy metabolism in chronic ischemic heart failure. J Ethnopharmacol. 2020; 246:112227. https://doi.org/10.1016/j.jep.2019.112227.

[69] Yang ZQ, Han YY, Gao F, et al. Shengxian decoction protects against chronic heart failure in a rat model via energy regulation mechanisms. BMC Compl Med Ther. 2023; 23(1):200. https://doi.org/10.1186/s12906-023-04035-3.

[70] Li YP, Ruan XF, Xu XW, et al. Shengmai Injection suppresses angiotensin II-induced cardiomyocyte hypertrophy and apoptosis via activation of the AMPK signaling pathway through energy-dependent mechanisms. Front Pharmacol. 2019; 10:1095. https://doi.org/10.3389/fphar.2019.01095.

[71] Wang Q, Wang X, Zhang DQ, et al. Transcriptome reveals the toxicity difference of dimethyl disulfide by contact and fumigation on Meloidogyne incognita through calcium channel-mediated oxidative phosphorylation. J Hazard Mater. 2023; 460:132268. https://doi.org/10.1016/j.jhazmat.2023.132268.

[72] Si XH, Shao M, Teng XY, et al. Mitochondrial isocitrate dehydrogenase impedes CAR T cell function by restraining antioxidant metabolism and histone acetylation. Cell Metab. 2024; 36(1):176-192.e10. https://doi.org/10.1016/j.cmet.2023.12.010.

[73] Chen HH, Wang SN, Cao TT, et al. Stachydrine hydrochloride alleviates pressure overload-induced heart failure and calcium mishandling on mice. J Ethnopharmacol. 2020; 248:112306. https://doi.org/10.1016/j.jep.2019.112306.

[74] Zhang Y, Zhang L, Zhang Y, et al. YiQiFuMai Powder Injection attenuates coronary artery ligation-induced heart failure through improving mitochondrial function via regulating ROS generation and CaMKII signaling pathways. Front Pharmacol. 2019; 10:381. https://doi.org/10.3389/fphar.2019.00381.

[75] Zhou ZY, Ma J, Zhao WR, et al. Qiangxinyin formula protects against isoproterenol-induced cardiac hypertrophy. Phytomedicine. 2024; 130:155717. https://doi.org/10.1016/j.phymed.2024.155717.

[76] Lu C, Li HL, Wang XT, et al. Investigating the mechanism of Chinese medicine formula AACO sgainst chronic heart failure by network pharmacology analysis and experimental validation. Altern Ther Health Med. 2024; 30(11):354-368.

[77] Yang XM, Wang QY, Zeng ZF, et al. The protective effect of Qishen Granule on heart failure after myocardial infarction through regulation of calcium homeostasis. Evid-Based Compl Alt. 2020; 2020:1868974. https://doi.org/10.1155/2020/1868974.

[78] Tan XY, Li JP, Wang XY, et al. Tanshinone IIA protects against cardiac hypertrophy via inhibiting calcineurin/NFATc3 pathway. Int J Biol Sci. 2011; 7(3):383-9. https://doi.org/10.7150/ijbs.7.383.

[79] Quintana-Cabrera R, Scorrano L. Determinants and outcomes of mitochondrial dynamics. Mol Cell. 2023; 83(6):857-876. https://doi.org/10.1016/j.molcel.2023.02.012.

[80] Donnarumma E, Kohlhaas M, Vimont E, et al. Mitochondrial fission process 1 controls inner membrane integrity and protects against heart failure. Nat Commun. 2022; 13(1):6634. https://doi.org/10.1038/s41467-022-34316-3.

[81] Liu L, Zhang WY, Liu TH, et al. The physiological metabolite α-ketoglutarate ameliorates osteoarthritis by regulating mitophagy and oxidative stress. Redox Biol. 2023; 62:102663. https://doi.org/10.1016/j.redox.2023.102663.

[82] Vargas JNS, Hamasaki M, Kawabata T, et al. The mechanisms and roles of selective autophagy in mammals. Nat Rev Mol Cell Biol. 2023; 24(3):167-185. https://doi.org/10.1038/s41580-022-00542-2.

[83] Li AQ, Gao M, Liu BL, et al. Mitochondrial autophagy: molecular mechanisms and implications for cardiovascular disease. Cell Death Dis. 2022; 13(5):444. https://doi.org/10.1038/s41419-022-04906-6.

[84] Guan ZJ, Chen J, Wang LH, et al. Nuanxinkang prevents the development of myocardial infarction-induced chronic heart failure by promoting PINK1/Parkin-mediated mitophagy. Phytomedicine. 2023; 108:154494. https://doi.org/10.1016/j.phymed.2022.154494.

[85] Yau WW, Singh BK, Lesmana R, et al. Thyroid hormone (T₃) stimulates brown adipose tissue activation via mitochondrial biogenesis and MTOR-mediated mitophagy. Autophagy. 2019; 15(1):131-150. https://doi.org/10.1080/15548627.2018.1511263.

[86] Sui YB, Xiu J, Wei JX, et al. Shen Qi Li Xin formula improves chronic heart failure through balancing mitochondrial fission and fusion via upregulation of PGC-1α. J Physiol Sci. 2021; 71(1):32. https://doi.org/10.1186/s12576-021-00816-y.

[87] Yang Y, Tian YS, Hu SY, et al. Extract of Sheng-Mai-San ameliorates myocardial ischemia-induced heart failure by modulating Ca²⁺-calcineurin-mediated Drp 1 signaling pathways. Int J Mol Sci. 2017; 18(9):1825. https://doi.org/10.3390/ijms18091825.

[88] Zhao QF, Li HR, Chang LP, et al. Qiliqiangxin attenuates oxidative stress-induced mitochondrion-dependent apoptosis in cardiomyocytes via PI3K/AKT/GSK3β signaling pathway. Biol Pharm Bull. 2019; 42(8):1310-1321. https://doi.org/10.1248/bpb.b19-00050.

[89] Li H, Mao YQ, Zhang Q, et al. Xinmailong mitigated epirubicin-induced cardiotoxicity via inhibiting autophagy. J Ethnopharmacol. 2016; 192:459-470. https://doi.org/10.1016/j.jep.2016.08.031.

[90] Long KL, Zhao ZY, Chen J, et al. Yang-xin-xue keli exerts therapeutic effects via regulating mitochondrial homeostasis and function in doxorubicin-induced rat heart failure. Front Pharmacol. 2022; 13:931453. https://doi.org/10.3389/fphar.2022.931453.

[91] Wang Z, Wang Y, Dong C, et al. Po-Ge-Jiu-Xin decoction alleviate sepsis-induced cardiomyopathy via regulating phosphatase and tensin homolog-induced putative kinase 1 /parkin-mediated mitophagy. J Ethnopharmacol. 2025; 337(Pt 3):118952. https://doi.org/10.1016/j.jep.2024.118952.

[92] Zhang XF, Wang QY, Wang XP, et al. Tanshinone IIA protects against heart failure post-myocardial infarction via AMPKs/mTOR-dependent autophagy pathway. Biomed Pharmacother. 2019; 112:108599. https://doi.org/10.1016/j.biopha.2019.108599.

[93] Fan CL, Tang XY, Ye MN, et al. Qi-Li-Qiang-Xin alleviates isoproterenol-induced myocardial injury by inhibiting excessive autophagy via activating AKT/mTOR pathway. Front Pharmacol. 2019; 10:1329. https://doi.org/10.3389/fphar.2019.01329.

[94] Ren PH, Zhang ZM, Wang P, et al. Yangxinkang Tablet protects against cardiac dysfunction and remodelling after myocardial infarction in rats through inhibition of AMPK/mTOR-mediated autophagy. Pharm Biol. 2020; 58(1):321-327. https://doi.org/10.1080/13880209.2020.1748662.

[95] Xu M, Wan CX, Huang SH, et al. Oridonin protects against cardiac hypertrophy by promoting P21-related autophagy. Cell Death Dis. 2019; 10(6):403. https://doi.org/10.1038/s41419-019-1617-y.

[96] Wang JY, Pu XY, Zhuang HW, et al. Astragaloside IV alleviates septic myocardial injury through DUSP1-Prohibitin 2 mediated mitochondrial quality control and ER-autophagy. J Adv Res. 2024. https://doi.org/10.1016/j.jare.2024.10.030.

[97] Fugh-Berman A. Herb-drug interactions. Lancet. 2000; 355(9198):134-138. https://doi.org/10.1016/s0140-6736(99)06457-0.